Trials / Recruiting
RecruitingNCT05093335
In-Human CXCR4 Imaging of Hematologic and Solid Tumors Using [68Ga]-Pentixafor-PET
In-human CXCR4 Imaging of Hematologic and Solid Tumors Using [68Ga]-Pentixafor-PET
- Status
- Recruiting
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the uptake of the imaging agent \[68Ga\]-pentixafor with PET/CT scans in people with monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), and non-Hodgkin lymphoma (NHL), or you have histiocytic neoplasms (Langerhans cell histiocytosis (LCH), Erdheim-Chester disease (ECD) and/or Rosai-Dorfman disease (RDD).
Conditions
- Non-Hodgkin Lymphoma
- Multiple Myeloma
- Histiocytic Neoplasms
- Erdheim-Chester Disease
- Rosai-Dorfman Disease
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | [68Ga]-Pentixafor | An intravenous bolus of 3 -5 mCi of \[68Ga\]-Pentixafor will be injected in all participants. |
Timeline
- Start date
- 2021-10-01
- Primary completion
- 2027-10-01
- Completion
- 2027-10-01
- First posted
- 2021-10-26
- Last updated
- 2026-02-05
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05093335. Inclusion in this directory is not an endorsement.